Developer docs
API playgroundTry for free, no card

Search company profiles

Cue Biopharma

Full company profile

uuid0000z6r

Namestring
Cue Biopharma
Legal namestring
Cue Biopharma, Inc.
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts (relocated from Cambridge), that designs biologics targeting disease-specific T cells for cancer, autoimmune disorders, and allergic disease. Its core technology is the proprietary Immuno-STAT® platform, which uses engineered IL-2 molecules with reduced alpha/beta subunit binding to selectively activate cytotoxic CD8+ T cells in vivo without broad immune modulation. The pipeline comprises CUE-221 (a dual-mechanism anti-IgE monoclonal antibody in Phase 2 development for chronic spontaneous urticaria and food allergy, in-licensed from Ascendant Health Sciences), CUE-401 (a bifunctional IL-2/TGF-B program for autoimmune and inflammatory disease advancing toward Phase 1), CUE-501 (B cell depletion molecules co-developed with Boehringer Ingelheim), and CUE-101 (a biologic for head and neck squamous cell carcinoma and other WT1-expressing tumors).

The company generates revenue almost exclusively through collaboration and licensing agreements with pharmaceutical partners, monetizing its platform via upfront payments, development and preclinical milestones (e.g., a $7.5M Boehringer Ingelheim preclinical milestone, a $15M upfront plus 40% equity stake from ImmunoScape, and up to $676.5M in potential milestones from the Ascendant deal) plus potential future royalties. Because Cue has no approved products, recurring capital is supplemented by repeated equity issuances, including a $30M PIPE in November 2022, a $10M public offering in December 2025, and a $30M private placement in May 2026. The company employs 11-50 staff, is led by President and CEO Shao-Lee Lin (appointed April 2026), and trades on Nasdaq under the ticker CUE.

Short descriptiontext

Cue Biopharma is a clinical-stage biopharmaceutical company that develops Immuno-STAT® biologics for cancer, autoimmune, and allergic diseases, monetizing its pipeline through pharmaceutical licensing and milestone-based collaborations with partners including Boehringer Ingelheim, ImmunoScape, and Ascendant Health Sciences.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-engineering therapeutics, clinical-stage biopharmaceutical, immuno-oncology biologics, autoimmune disease therapeutics, T cell receptor platform
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration and Licensing Revenue
TypeLicensing Royalties
Description

Revenue generated from strategic collaborations with pharmaceutical partners including upfront payments, milestone payments, and potential royalties on future product sales. Recent deals include ImmunoScape collaboration ($15M upfront + 40% equity stake) and Boehringer Ingelheim milestone payments ($7.5M preclinical milestone).

globenewswire.com
2Public Equity Offerings
TypeOne Time License
Description

Capital raised through public offerings of common stock and warrants to fund clinical development and operations.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Immuno-STAT
Description

Platform technology that selectively targets disease-specific T cells in vivo without broad immune modulation.

cuebiopharma.com
Core offering1 text field

Cue Biopharma is a clinical-stage biopharmaceutical company that develops precision immuno-engineered biologic therapeutics using its proprietary Immuno-STAT® platform. Its pipeline includes CUE-221 (Phase 2 anti-IgE antibody for allergic diseases), CUE-401 (bifunctional IL-2/TGF-B for autoimmune disease), CUE-501 (B cell depletion molecules for autoimmune disease via Boehringer Ingelheim), and CUE-101 (oncology biologic for head and neck squamous cell carcinoma). Revenue is generated through collaboration agreements, licensing deals, and milestone payments from pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 results for Ascendant-221 in chronic spontaneous urticaria expected in H2 2026
+2 more records
Product overview1 text field

Cue Biopharma is a clinical-stage biopharmaceutical company with a portfolio of therapeutic candidates. The company's lead products include CUE-221 (Phase 2 anti-IgE antibody for allergic diseases) and CUE-401 (Phase 1 bifunctional IL-2/TGF-B program for autoimmune diseases). These are supported by the Immuno-STAT® platform technology for targeted T cell modulation. Additional pipeline candidates include CUE-501 (B cell depletion molecules for autoimmune diseases, via Boehringer Ingelheim collaboration) and CUE-101 (biologic for head and neck squamous cell carcinoma and other cancers).

Product and service5 records
1CUE-221
CategoryBiologic Therapeutic - Anti-IgE Antibody
Description

A novel anti-IgE monoclonal antibody with a dual-mechanism of action for IgE-mediated allergic diseases, currently in Phase 2 development for chronic spontaneous urticaria and food allergy. Acquired via exclusive global license from Ascendant Health Sciences Ltd. (excluding mainland China, Hong Kong, Macau and Taiwan).

2CUE-401
CategoryBiologic Therapeutic - Bifunctional IL-2/TGF-B
Description

A bifunctional IL-2 and TGF-B program designed to regulate inflammation and drive regulatory T cell-mediated tolerance for autoimmune and inflammatory diseases, advancing towards Phase 1 development.

3CUE-501
CategoryBiologic Therapeutic - B Cell Depletion Molecule
Description

B cell depletion molecules developed in collaboration with Boehringer Ingelheim, targeting autoimmune and inflammatory diseases. Currently in lead optimization under the collaboration, which may include additional R&D opportunities beyond the initial agreement.

4CUE-101
CategoryBiologic Therapeutic - Oncology
Description

A clinical-stage biologic therapy designed to selectively modulate disease-specific T cells, targeting cancers such as head and neck squamous cell carcinoma and cancers that over-express Wilms' Tumor 1 (WT1) antigen. Developed on the Immuno-STAT® platform for targeted immunotherapy in oncology.

5Immuno-STAT® Platform
CategoryProprietary Immuno-Engineering Platform
Description

Cue Biopharma's proprietary immuno-engineering platform technology that selectively targets disease-specific T cells in vivo without broad immune modulation. Built around engineered IL-2 molecules with modifications to reduce binding to alpha and beta subunits of the IL-2 receptor, enabling targeted activation of cytotoxic CD8+ T cells and supporting multiple pipeline candidates across oncology, autoimmune, and allergic disease.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Collaboration on B cell depletion molecules including CUE-501 product targeting autoimmune and inflammatory diseases. Cue Biopharma received a $7.5 million preclinical milestone payment following approval of first compound for lead optimization. The collaboration includes potential for additional research and development opportunities expanding upon the initial agreement.

in.investing.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Strategic collaboration and license agreement to develop next-generation T cell therapy approach targeting solid tumors. The partnership combines Cue's Immuno-STAT platform with ImmunoScape's TCR technology, with IND submission targeted for 2027. Cue received $15 million upfront payment and 40% equity stake in the collaboration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing T cell engagers for cancer using a proprietary tumor-activated T cell engager (TRACTr) platform, directly comparable as a small-cap immunology/oncology biologic developer with platform technology and partnered programs.

TypeEmerging player
Description

Clinical-stage antibody discovery platform company partnering with pharma to develop antibody therapeutics across multiple indications, including immunology; directly comparable in its platform-as-a-licensing engine and partnered pipeline structure.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer using a proprietary POWERbody and SAFEbody discovery platform, with a similar pipeline breadth and licensing-driven business model to Cue Biopharma.

TypeDirect peer
Description

Clinical-stage cancer immunotherapy company using a computational platform to identify novel drug targets and develop antibody-based therapeutics; comparable in its use of platform-based discovery to generate pipeline assets and its focus on selective immune modulation.

TypeEmerging player
Description

Clinical-stage company developing antibody-drug conjugates and immuno-oncology therapeutics with a focus on tumor-microenvironment biology; comparable as a small-cap developer of selective biologic immunotherapies and a recent leadership transition.

TypeBroad incumbent
Description

Mid-cap clinical-stage immuno-oncology company with multiple programs targeting the adenosine pathway and T cell checkpoints, partnered with Gilead; directly comparable as an immuno-oncology focused developer, but with a larger pipeline and deeper capital base.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that selectively activate tumors; relevant as a fellow small-cap developer of immune-targeted biologics with a partnered Phase 1/2 pipeline.

TypeBroad incumbent
Description

Clinical-stage immunology company developing therapeutics for infectious diseases and serious immunologic conditions, with multiple partnered programs and a platform-driven approach; broader and more capitalized than Cue but a relevant benchmark for immunology-focused biotechs.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing biologic therapeutics for cancer and autoimmune diseases, with a similarly small cap, multi-asset pipeline, and platform-based discovery approach comparable to Cue Biopharma's Immuno-STAT strategy.

TypeDirect peer
Description

Clinical-stage oncology company developing PREDATOR platform-based conditionally activated immunotherapies for cancer; comparable in scale, therapeutic focus on immune-mediated oncology, and partnership-driven development model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cue Biopharma

Clinical-Stage Biopharmaceutical Therapeuticscuebiopharma.com

Cue Biopharma is a clinical-stage biopharmaceutical company that develops Immuno-STAT® biologics for cancer, autoimmune, and allergic diseases, monetizing its pipeline through pharmaceutical licensing and milestone-based collaborations with partners including Boehringer Ingelheim, ImmunoScape, and Ascendant Health Sciences.

What Cue Biopharma does

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts (relocated from Cambridge), that designs biologics targeting disease-specific T cells for cancer, autoimmune disorders, and allergic disease. Its core technology is the proprietary Immuno-STAT® platform, which uses engineered IL-2 molecules with reduced alpha/beta subunit binding to selectively activate cytotoxic CD8+ T cells in vivo without broad immune modulation. The pipeline comprises CUE-221 (a dual-mechanism anti-IgE monoclonal antibody in Phase 2 development for chronic spontaneous urticaria and food allergy, in-licensed from Ascendant Health Sciences), CUE-401 (a bifunctional IL-2/TGF-B program for autoimmune and inflammatory disease advancing toward Phase 1), CUE-501 (B cell depletion molecules co-developed with Boehringer Ingelheim), and CUE-101 (a biologic for head and neck squamous cell carcinoma and other WT1-expressing tumors).

The company generates revenue almost exclusively through collaboration and licensing agreements with pharmaceutical partners, monetizing its platform via upfront payments, development and preclinical milestones (e.g., a $7.5M Boehringer Ingelheim preclinical milestone, a $15M upfront plus 40% equity stake from ImmunoScape, and up to $676.5M in potential milestones from the Ascendant deal) plus potential future royalties. Because Cue has no approved products, recurring capital is supplemented by repeated equity issuances, including a $30M PIPE in November 2022, a $10M public offering in December 2025, and a $30M private placement in May 2026. The company employs 11-50 staff, is led by President and CEO Shao-Lee Lin (appointed April 2026), and trades on Nasdaq under the ticker CUE.

Cue Biopharma firmographics

Firmographics
Name
Cue Biopharma
Legal name
Cue Biopharma, Inc.
Website
https://cuebiopharma.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Cue Biopharma is a clinical-stage biopharmaceutical company that develops Immuno-STAT® biologics for cancer, autoimmune, and allergic diseases, monetizing its pipeline through pharmaceutical licensing and milestone-based collaborations with partners including Boehringer Ingelheim, ImmunoScape, and Ascendant Health Sciences.
Ownership category
akta.pro rank

Cue Biopharma industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Immuno-engineering therapeutics
  • Clinical-stage biopharmaceutical
  • Immuno-oncology biologics
  • Autoimmune disease therapeutics
  • T cell receptor platform

Where Cue Biopharma is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cue Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Collaboration and Licensing Revenue: Revenue generated from strategic collaborations with pharmaceutical partners including upfront payments, milestone payments, and potential royalties on future product sales. Recent deals include ImmunoScape collaboration ($15M upfront + 40% equity stake) and Boehringer Ingelheim milestone payments ($7.5M preclinical milestone).
  2. Public Equity Offerings: Capital raised through public offerings of common stock and warrants to fund clinical development and operations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Cue Biopharma product offering

Product offering

Core offering

Cue Biopharma is a clinical-stage biopharmaceutical company that develops precision immuno-engineered biologic therapeutics using its proprietary Immuno-STAT® platform. Its pipeline includes CUE-221 (Phase 2 anti-IgE antibody for allergic diseases), CUE-401 (bifunctional IL-2/TGF-B for autoimmune disease), CUE-501 (B cell depletion molecules for autoimmune disease via Boehringer Ingelheim), and CUE-101 (oncology biologic for head and neck squamous cell carcinoma). Revenue is generated through collaboration agreements, licensing deals, and milestone payments from pharmaceutical partners.

Product overview

Cue Biopharma is a clinical-stage biopharmaceutical company with a portfolio of therapeutic candidates. The company's lead products include CUE-221 (Phase 2 anti-IgE antibody for allergic diseases) and CUE-401 (Phase 1 bifunctional IL-2/TGF-B program for autoimmune diseases). These are supported by the Immuno-STAT® platform technology for targeted T cell modulation. Additional pipeline candidates include CUE-501 (B cell depletion molecules for autoimmune diseases, via Boehringer Ingelheim collaboration) and CUE-101 (biologic for head and neck squamous cell carcinoma and other cancers).

Differentiator

Problem solved

Functional benefit

Brands

  • Immuno-STAT: Platform technology that selectively targets disease-specific T cells in vivo without broad immune modulation.

Products and services

  • CUE-221 A novel anti-IgE monoclonal antibody with a dual-mechanism of action for IgE-mediated allergic diseases, currently in Phase 2 development for chronic spontaneous urticaria and food allergy. Acquired via exclusive global license from Ascendant Health Sciences Ltd. (excluding mainland China, Hong Kong, Macau and Taiwan).
  • CUE-401 A bifunctional IL-2 and TGF-B program designed to regulate inflammation and drive regulatory T cell-mediated tolerance for autoimmune and inflammatory diseases, advancing towards Phase 1 development.
  • CUE-501 B cell depletion molecules developed in collaboration with Boehringer Ingelheim, targeting autoimmune and inflammatory diseases. Currently in lead optimization under the collaboration, which may include additional R&D opportunities beyond the initial agreement.
  • CUE-101 A clinical-stage biologic therapy designed to selectively modulate disease-specific T cells, targeting cancers such as head and neck squamous cell carcinoma and cancers that over-express Wilms' Tumor 1 (WT1) antigen. Developed on the Immuno-STAT® platform for targeted immunotherapy in oncology.
  • Immuno-STAT® Platform Cue Biopharma's proprietary immuno-engineering platform technology that selectively targets disease-specific T cells in vivo without broad immune modulation. Built around engineered IL-2 molecules with modifications to reduce binding to alpha and beta subunits of the IL-2 receptor, enabling targeted activation of cytotoxic CD8+ T cells and supporting multiple pipeline candidates across oncology, autoimmune, and allergic disease.

Quantifiable outcome

  • Phase 2 results for Ascendant-221 in chronic spontaneous urticaria expected in H2 2026
  • +2 more outcomes

Companies that use Cue Biopharma

Customer profile

Segments3 records

Ideal customer profiles2 records

Cue Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cue Biopharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 1 April 2026Collaboration on B cell depletion molecules including CUE-501 product targeting autoimmune and inflammatory diseases. Cue Biopharma received a $7.5 million preclinical milestone payment following approval of first compound for lead optimization. The collaboration includes potential for additional research and development opportunities expanding upon the initial agreement.
  • ImmunoScapecoreStrategic or Co-development Partner · 1 November 2025Strategic collaboration and license agreement to develop next-generation T cell therapy approach targeting solid tumors. The partnership combines Cue's Immuno-STAT platform with ImmunoScape's TCR technology, with IND submission targeted for 2027. Cue received $15 million upfront payment and 40% equity stake in the collaboration.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Cue Biopharma competitors and assessment

Company assessment

Direct peers

  • Janux Therapeutics: Clinical-stage company developing T cell engagers for cancer using a proprietary tumor-activated T cell engager (TRACTr) platform, directly comparable as a small-cap immunology/oncology biologic developer with platform technology and partnered programs.
  • Adagene: Clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer using a proprietary POWERbody and SAFEbody discovery platform, with a similar pipeline breadth and licensing-driven business model to Cue Biopharma.
  • Compugen: Clinical-stage cancer immunotherapy company using a computational platform to identify novel drug targets and develop antibody-based therapeutics; comparable in its use of platform-based discovery to generate pipeline assets and its focus on selective immune modulation.
  • Inhibrx Biosciences: Clinical-stage biopharmaceutical company developing biologic therapeutics for cancer and autoimmune diseases, with a similarly small cap, multi-asset pipeline, and platform-based discovery approach comparable to Cue Biopharma's Immuno-STAT strategy.
  • Werewolf Therapeutics: Clinical-stage oncology company developing PREDATOR platform-based conditionally activated immunotherapies for cancer; comparable in scale, therapeutic focus on immune-mediated oncology, and partnership-driven development model.

Emerging players

  • AbCellera Biologics: Clinical-stage antibody discovery platform company partnering with pharma to develop antibody therapeutics across multiple indications, including immunology; directly comparable in its platform-as-a-licensing engine and partnered pipeline structure.
  • Pyxis Oncology: Clinical-stage company developing antibody-drug conjugates and immuno-oncology therapeutics with a focus on tumor-microenvironment biology; comparable as a small-cap developer of selective biologic immunotherapies and a recent leadership transition.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that selectively activate tumors; relevant as a fellow small-cap developer of immune-targeted biologics with a partnered Phase 1/2 pipeline.

Broad incumbents

  • Arcus Biosciences: Mid-cap clinical-stage immuno-oncology company with multiple programs targeting the adenosine pathway and T cell checkpoints, partnered with Gilead; directly comparable as an immuno-oncology focused developer, but with a larger pipeline and deeper capital base.
  • Vir Biotechnology: Clinical-stage immunology company developing therapeutics for infectious diseases and serious immunologic conditions, with multiple partnered programs and a platform-driven approach; broader and more capitalized than Cue but a relevant benchmark for immunology-focused biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Cue Biopharma social profiles

Digital presence

Cue Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cue Biopharma leadership team

Management profile

Number of profiles

Profiles6 records

Cue Biopharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cue Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cue Biopharma

What does Cue Biopharma do?

Cue Biopharma is a clinical-stage biopharmaceutical company that develops precision immuno-engineered biologic therapeutics using its proprietary Immuno-STAT® platform. Its pipeline includes CUE-221 (Phase 2 anti-IgE antibody for allergic diseases), CUE-401 (bifunctional IL-2/TGF-B for autoimmune disease), CUE-501 (B cell depletion molecules for autoimmune disease via Boehringer Ingelheim), and CUE-101 (oncology biologic for head and neck squamous cell carcinoma). Revenue is generated through collaboration agreements, licensing deals, and milestone payments from pharmaceutical partners.

Is Cue Biopharma a public or private company?

Cue Biopharma is a public company. It is classified as public and is currently operating.

When was Cue Biopharma founded?

Cue Biopharma was founded in 2016. It employs 11 to 50 people.

Where is Cue Biopharma based?

Cue Biopharma is headquartered in Boston, United States, in the North America region.

How does Cue Biopharma make money?

Two revenue lines are on record. Collaboration and Licensing Revenue is the primary driver. The others are public Equity Offerings.

Who are Cue Biopharma's main competitors?

Direct peers on record are Janux Therapeutics, Adagene, Compugen, Inhibrx Biosciences and Werewolf Therapeutics. Emerging players are AbCellera Biologics, Pyxis Oncology and Bolt Biotherapeutics. Broad incumbents are Arcus Biosciences and Vir Biotechnology.

Does Cue Biopharma have an API?

No public API is recorded for Cue Biopharma.

What industry is Cue Biopharma in?

Cue Biopharma's product category is Clinical-Stage Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCue Biopharma (CUE) Stock Fair Value Moves Lower As CUE 221 Debate Clouds OutlookAnalyst fair value for Cue Biopharma fell from $88 to about $68.67, a cut of over 20%, amid debate over CUE-221's pharmacokinetics versus efficacy. B. Riley's price target dropped from $83 to $25, reflecting caution on trial design and execution risks.Simply Wall StIs Cue Biopharma (NASDAQ:CUE) In A Good Position To Deliver On Growth Plans?Cue Biopharma had a cash runway of about 14 months as of September 2026, with $58m cash and $51m annual cash burn. Its cash burn rose 72% year-over-year, while revenue grew 402%, but the burn represented 50% of its $102m market cap, raising concerns about future capital raising.Investing.comB.Riley cuts Cue Biopharma stock price target on financing concernsB.Riley cut its price target on Cue Biopharma to $25 from $83, citing financing concerns, while keeping a Buy rating. The stock fell 84.83% in a week, but the firm said the sell-off was excessive given unchanged clinical efficacy for CUE-221. The company's multi-year financing path remains the largest driver of the cut.Quiver Quantitative$CUE stock is down 70% today. Here's what we see in our data. | CUE Stock NewsCUE stock fell 70% today, with $10.26 million in trading volume. Insiders sold 15 times in six months, including CEO Lin selling 69,345 shares. Hedge funds added 34 positions while 36 reduced them.The future of tradingCue Biopharma, Inc. <cue.oq> expected to post a loss of $2.24 a share - Earnings PreviewCue Biopharma is expected to report a 51.9% revenue drop to $1.033 million for the quarter ending September 30, 2026, and a loss of $2.24 per share. Analysts rate the stock a strong buy, with a median price target of $83.00, about 343% above the last closing price.Ticker ReportAnalyzing HCW Biologics (NASDAQ:HCWB) and Cue Biopharma (NASDAQ:CUE)Cue Biopharma and HCW Biologics are compared on profitability, valuation, risk, and analyst ratings. HCW Biologics has higher earnings and a higher price target, while Cue Biopharma is more affordable. Analysts favor HCW Biologics due to its higher probable upside.Investing.comCue Biopharma’s chief legal officer sells $51,724 in stockCue Biopharma's chief legal officer sold 1,844 shares at $28.05 each, totaling $51,724, on October 12, 2026, as part of a sell-to-cover transaction. The stock has since dropped to $18.60, but B.Riley reiterated a Buy rating with a $83 price target.Investing.comCue Biopharma’s chief legal officer sells $51,724 in stockCue Biopharma's chief legal officer sold 1,844 shares on October 12, 2026, at $28.05 per share, totaling $51,724, in a sell-to-cover transaction for tax withholding. The stock has since fallen to $18.60, but B.Riley reiterated a Buy rating with a $83 price target.Markets DailyCue Biopharma, Inc. (NASDAQ:CUE) Shares Shorted: Short Interest Up 111.4% in SeptemberShort interest in Cue Biopharma rose 111.4% to 702,198 shares as of September 30, with 11.3% of shares short sold. The company reported Q2 EPS of -$24.14, missing the -$1.69 consensus by $22.45, while revenue of $7.88 million beat estimates. Analysts have an average "Hold" rating with a $83 target.MarketBeatCue Biopharma, Inc. (NASDAQ:CUE) Sees Large Growth in Short InterestCue Biopharma's short interest surged 111.4% to 702,198 shares as of September 30th, with 11.3% of shares sold short. Insiders sold 72,715 shares over the past 90 days, and the stock traded down 11% to $21.90. Analysts rate the stock a Hold with an average price target of $83.